A Double-blind, Escalating Dose, Randomized, Placebo-controlled Study Assessing PK, Safety, Tolerability in Non-ambulant DMD Subjects

NCT01128855 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Muscular Dystrophies

Interventions

DRUG: 3 mg/kg GSK2402968
DRUG: 6 mg/kg GSK2402968
DRUG: 9 mg/kg GSK2402968
DRUG: 12 mg/kg GSK2402968
OTHER: Placebo

Sponsor

GlaxoSmithKline